Remibrutinib (Open Label)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Moein Amin

Conditions

Generalized Myasthenia GravisMultiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Primary ProgressiveMultiple Sclerosis (MS) Secondary ProgressiveSecondary Progressive Multiple Sclerosis (SPMS)

Phase 2

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Not yet recruitingNCT07222956

Moein AminMultiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive

Start: 2027-03-01End: 2030-12-30Target: 20Updated: 2026-08-19

Phase 3

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

RecruitingNCT06744920

Novartis PharmaceuticalsGeneralized Myasthenia Gravis

Start: 2025-02-07End: 2033-02-26Target: 180Updated: 2026-07-29

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

RecruitingNCT07225504

Novartis PharmaceuticalsSecondary Progressive Multiple Sclerosis (SPMS)

Start: 2025-11-11End: 2034-01-02Target: 1275Updated: 2026-07-29